Most importantly, the p21 induction observed herein, in response to TH301 treatment, seems to occur independently of both CRY2 and BMAL1 modulation, thus indicating the involvement of alternative pathways, successfully operating in pancreatic cancer cell environments of diverse mutational loads. The gene discussed is CDKN1A; the disease is familial pancreatic carcinoma.